SMTI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sanara Medtech Inc (SMTI) is not a strong buy at the moment for a beginner, long-term investor. The stock lacks clear positive trading signals, and while the company shows revenue growth, its financials still reflect significant net losses. Additionally, the technical indicators and stock trend analysis do not suggest a favorable entry point currently.
The MACD is above 0 but positively contracting, indicating weakening momentum. RSI is neutral at 31.621, and moving averages are converging, showing no clear trend. The stock is trading near its S2 support level of 18.762, but the overall technical setup does not strongly favor a buy.
Revenue increased by 21.51% YoY in Q3 2025, and gross margin improved to 90.56%. The company focuses on innovative technologies in the surgical market, which could drive long-term growth.
Stock trend analysis suggests a likelihood of further short-term declines (-2.55% in the next week, -3.18% in the next month). No significant hedge fund or insider activity.
In Q3 2025, revenue grew by 21.51% YoY to $26.33M, but net income remains deeply negative at -$30.41M, albeit improving by 964.16% YoY. EPS also remains negative at -3.52, up 935.29% YoY. Gross margin improved to 90.56%, up 3.39% YoY.
No recent analyst rating or price target updates available.
